TITLE:
A Single Centre Experience with Phenotype Dependent Perioperative Chemotherapy for Primary Breast Cancer
AUTHORS:
Tamás Kullmann, Kofi Agyemang-Prempeh, Adél Ambrus, Gabriella Herodek, Balázs Hillier, Károly Kocsis, Ilona Laszip, Mária Mák, Tamás Pintér, István Sipőcz
KEYWORDS:
Breast Cancer, Carboplatin, Trastuzumab, Adjuvant, Neoadjuvant
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.10 No.1,
January
4,
2019
ABSTRACT: Background:
Standard adjuvant or neo-adjuvant chemotherapy of primary breast cancers
consists of docetaxel and the combination of anthracyclin-cyclophosphamide
in two steps. According to international literature, the neo-adjuvant treatment of triple negative
tumours by the combination of docetaxel-carboplatin allows a high rate of
pathological complete remission and the adjuvant treatment of small, node
negative HER2+ tumours by the combination of paclitaxel-trastuzumab allows a
negligible recurrence rate together with a very good tolerance. Methods: Our
aim was the retrospective analysis of the alternative chemotherapy regimens in
our patient population. Results: The neo-adjuvant docetaxel-carboplatin allowed
a 55% pathological complete remission rate among 20 patients. With the adjuvant
paclitaxel-trastuzumab, we did not notice any recurrence among 5 patients
at a median follow-up of 18 months. Conclusion: Our results correspond
to the literature data. The spread of the protocols in the clinical practice is
proposed.